COVID-19 mRNA vaccine
- Generic Name
- COVID-19 mRNA vaccine
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
- Conditions
- SARS-CoV-2SARS-CoV
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Vaccine Company, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT05938075
- Locations
- 🇿🇦
Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Academic Hospital, Johannesburg, Gauteng, South Africa
🇿🇦HIV and other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council, Botha's Hill, Kwa-Zulu Natal, South Africa
Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05373472
- Locations
- 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China
🇨🇳Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
🇨🇳Hebei Petro China Center Hospital, Langfang, Hebei, China
Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT05373485
- Locations
- 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China
🇨🇳Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
🇨🇳Hebei Petro China Center Hospital, Langfang, Hebei, China
Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 10285
- Registration Number
- NCT05204589
- Locations
- 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.